Form 4: Aura Biosciences CMO Sells Shares for Tax Obligations

Aura Biosciences' Chief Medical Officer, Janet Jill Hopkins, sold 17,109 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Janet Jill Hopkins, Chief Medical Officer of Aura Biosciences, Inc. (AURA), reported a sale of common stock.
• The transaction occurred on November 17, 2025.
• A total of 17,109 shares were sold at a weighted average price of $5.42 per share, with prices ranging from $5.42 to $5.44.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units and was automatic, not discretionary.
• Following this transaction, Ms. Hopkins beneficially owns 252,685 shares of Aura Biosciences common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive because the insider sale was non-discretionary and for tax purposes, which is a routine event and does not signal a lack of confidence in the company by the insider.

Positives

• The sale was non-discretionary and solely for tax withholding purposes, indicating it was not a voluntary decision to reduce exposure to the company.

Negatives

• A reduction in direct insider ownership, even if for tax purposes, slightly decreases the alignment of management's personal financial interests with shareholders.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Management Comments

• The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information relevant to broader industry trends or competitor analysis.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the non-discretionary nature for tax purposes mitigates concerns about management's confidence.

Key Dates

Recommendation

This Form 4 details a routine, non-discretionary sale of shares by an executive to cover tax obligations arising from RSU vesting. Such transactions are common and do not typically reflect a change in the executive's outlook on the company's prospects. Therefore, this filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation. Investors should continue to evaluate the company based on its operational performance, financial results, and strategic developments.

Keywords

Aura Biosciences, AURA, Insider transaction, Form 4, Stock sale, Chief Medical Officer, RSU vesting, Tax withholding, Equity compensation